Replicated international studies have underscored the human and societal costs associated
with major depressive disorder. Despite the proven efficacy of monoamine-based …

Anxiety disorders are the most prevalent psychiatric disorders and a leading cause of
disability. While there continues to be expansive research in posttraumatic stress disorder …

Major depressive disorder (MDD) is a disabling medical condition associated with significant
morbidity, mortality and public health costs. However, neurocircuitry abnormalities …

Objective: Major depressive disorder is characterized by impaired reward processing,
possibly due to dysfunction in the basal ganglia. However, few neuroimaging studies of …

Objective Ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, has
shown rapid antidepressant effects, but small study groups and inadequate control …

Background Ketamine is reported to have rapid antidepressant effects; however, there is
limited understanding of the time-course of ketamine effects beyond a single infusion. A …

Background The N-methyl-D-aspartate glutamate receptor antagonist ketamine, delivered
via an intravenous route, has shown rapid antidepressant effects in patients with treatment …

Objective To quantify the impact of citalopram and other selective serotonin reuptake
inhibitors on corrected QT interval (QTc), a marker of risk for ventricular arrhythmia, in a large …

Background Preliminary evidence suggests intravenous ketamine has rapid effects on
suicidal cognition, making it an attractive candidate for depressed patients at imminent risk …

Background Longitudinal studies of illness progression in patients with major depressive
disorder (MDD) indicate that the onset of subsequent depressive episodes becomes …